ArticleJournal of neuro-oncology2026
CRYM suppresses glioblastoma progression by inhibiting the TGFβ1/Smad-EMT signaling pathway.
Article in Journal of neuro-oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe role and mechanism of the CRYM gene in glioblastoma (GBM) remain unknown to date. Therefore, this study aims to report the abnormal expression of CRYM in glioblastoma and elucidate its function and underlying mechanism in GBM.
methodsUsing quantitative polymerase chain reaction (qRT-PCR) and western blotting(WB), we investigated the differential expression levels of CRYM between normal cells and various glioma cell lines, as well as between normal brain tissues and tumor tissues from patients with different grades of glioma. After overexpressing CRYM in various glioma cell lines via plasmid transfection, we demonstrated the role of CRYM in glioma cells through CCK-8, Transwell, wound healing, and EdU assays. The mechanism of CRYM in glioblastoma was elucidated using WB and a TGFβ1 agonist. In animal in vivo experiments, we further revealed the inhibitory effect of CRYM overexpression on glioblastoma proliferation in nude mice via subcutaneous ectopic and intracranial orthotopic glioma transplantation models.
resultsThe results demonstrated that CRYM expression was significantly downregulated in glioma cell lines compared to normal cell lines. Similarly, clinical glioma tissue samples exhibited lower CRYM levels than normal brain tissues, with expression decreasing progressively as glioma grade increased. Overexpression of CRYM markedly suppressed the proliferation and invasion of GBM cells in vitro. These findings were further corroborated by in vivo models, wherein CRYM overexpression significantly inhibited tumor growth in both subcutaneous ectopic and intracranial orthotopic xenograft assays. Bioinformatic analysis and WB revealed that CRYM exerts its tumor-suppressive effects primarily by inhibiting the TGFβ1/Smad signaling pathway and epithelial-mesenchymal transition (EMT).
conclusionHigh expression of CRYM significantly suppresses GBM progression by inhibiting the TGFβ1/Smad signaling pathway and EMT, suggesting CRYM as a potential therapeutic target for GBM. Furthermore, CRYM may also serve as a promising biomarker for the diagnosis and prognosis of GBM.
Indexed as
Identifiers
41973277What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.